融捷健康(300247) - 2021 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2021 was CNY 141,962,434.91, representing a 24.71% increase compared to CNY 113,831,468.13 in the same period last year[8]. - The net profit attributable to shareholders was CNY 8,192,592.25, a significant turnaround from a loss of CNY 15,407,677.21, marking a 153.17% improvement[8]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 7,629,271.47, compared to a loss of CNY 15,442,503.23, reflecting a 149.40% increase[8]. - The company's operating revenue increased by 28.13 million yuan, a growth of 24.71% year-on-year, and excluding the revenue from the sold subsidiary Shanghai Ruiyu, the revenue increased by 63.16 million yuan, a growth of 80.15%[25]. - The company's net profit attributable to ordinary shareholders increased by 8.19 million yuan, a rise of 153.17% year-on-year[33]. - The total comprehensive income attributable to the parent company was CNY 10,203,072.50, compared to a loss of CNY 15,832,919.16 in the same period last year[58]. - The basic and diluted earnings per share for the quarter were CNY 0.0102, recovering from a loss of CNY 0.0192 in the previous year[58]. Cash Flow and Assets - The net cash flow from operating activities was CNY 9,442,728.18, up 10.17% from CNY 8,570,859.68 in the previous year[8]. - Cash inflow from operating activities totaled ¥46,543,317.02, significantly increasing from ¥20,014,361.40 in the previous period[67]. - The cash flow from financing activities generated a net inflow of ¥21,188,932.83, with total cash outflow amounting to ¥8,811,067.17[69]. - The company's cash and cash equivalents decreased to CNY 30,079,500.33 from CNY 74,412,506.96, a decline of 59.6%[51]. - The total cash outflow from investing activities was ¥66,817,526.40, down from ¥128,906,430.32 in the previous period, resulting in a net cash flow from investing activities of -¥45,539,059.46[69]. Assets and Liabilities - The total assets at the end of the reporting period were CNY 956,476,863.59, a slight decrease of 0.01% from CNY 956,578,278.65 at the end of the previous year[8]. - The company's current assets decreased to CNY 452,996,227.43 from CNY 482,597,303.79, reflecting a decline of approximately 6.1%[48]. - The total liabilities decreased to CNY 67,423,555.92 from CNY 79,189,997.84, reflecting a decline of about 15%[49]. - Total liabilities decreased to CNY 162,864,008.58 from CNY 166,927,541.65 at the end of 2020, a reduction of 2.0%[54]. Operational Efficiency - The gross profit margin improved from 23.22% to 25.36% during the reporting period[32]. - Total operating costs for Q1 2021 were CNY 130,707,253.35, up from CNY 121,479,126.10 in the same period last year, representing an increase of 7.9%[57]. - The company's accounts receivable decreased by 32.98%, down CNY 14,598,800, mainly due to the collection of previous receivables[20]. - Sales expenses decreased by 7.19 million yuan, a decline of 38.72%, mainly due to Shanghai Ruiyu not being included in the consolidated financial statements[26]. Investment and Development - Investment income increased by 7.34 million yuan, a growth of 105.54%, primarily due to the exclusion of investment income from sold subsidiaries[28]. - Research and development expenses for Q1 2021 were CNY 2,876,376.21, down from CNY 3,158,771.86 in Q1 2020, a decrease of 8.9%[57]. - Research and development expenses increased to CNY 1,907,048.63, up from CNY 607,057.48, indicating a focus on innovation[61]. Strategic Initiatives - The company plans to optimize its supply chain and strengthen supplier relationships to mitigate risks from raw material price fluctuations[35]. - The company aims to accelerate new product development and enhance brand value to improve market competitiveness[35]. Compliance and Governance - The company reported no violations regarding external guarantees during the reporting period[41]. - There were no non-operating fund occupations by controlling shareholders or related parties during the reporting period[42]. - The company did not experience any significant changes in project feasibility or issues with the use of raised funds[40].